Genredigerande läkemedel sänker det onda kolesterolet med 62 procent i studie

28 maj 2026

Rapporterad av AI

En experimentell terapi vid namn VERVE-102 sänkte LDL-kolesterolet med upp till 62 procent efter en enstaka dos i en tidig säkerhetsstudie. Resultaten kommer från en fas I-studie med 35 patienter som lider av högt kolesterol eller tidig hjärt-kärlsjukdom. Data publicerades denna vecka i New England Journal of Medicine.

Forskare rapporterade att behandlingen verkade säker, utan några allvarliga biverkningar ens vid den högsta dosen. Deltagarna upplevde endast en tillfällig mild ökning av leverenzymer. Läkemedlet använder mRNA förpackat i nanopartiklar för att redigera PCSK9-genen i leverceller, vilket permanent minskar produktionen av ett protein som höjer LDL-nivåerna.

Relaterade artiklar

Scientific illustration of HELZ2 protein in the liver regulating cholesterol release.

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

25 maj 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

Scientists at UT Southwestern Medical Center report they have identified a protein, HELZ2, that acts as a key regulator of how many cholesterol-carrying particles the liver releases into the bloodstream by affecting the gene APOB. The study was published in the American Heart Association journal Circulation and could inform future research into heart disease and fatty liver disease.

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

DNA hairpin molecules lowered cholesterol by 47% in mice by silencing PCSK9, researchers report

1 maj 2026 Rapporterad av AI Faktagranskad

Researchers from the University of Barcelona and the University of Oregon report that short DNA molecules known as polypurine reverse Hoogsteen hairpins (PPRHs) suppressed the PCSK9 gene and reduced blood cholesterol in a mouse model. In transgenic mice carrying the human PCSK9 gene, a single injection of one candidate (HpE12) cut plasma PCSK9 by 50% and total cholesterol by 47% three days later, according to findings published in Biochemical Pharmacology.

Hälsa

Virus injection halts pancreatic tumor growth in trial

Hälsa

UCLA scientists reverse liver damage in mice by removing zombie cells

Hälsa

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Compound X clears Parkinson's proteins in mice brains

Researchers in Australia have found that a mysterious FDA-approved drug, called compound X, removes toxic alpha-synuclein proteins from the brains of mice with Parkinson's-like symptoms. The treatment improved the animals' balance and mobility by enhancing the brain's glymphatic waste disposal system. The findings were presented at a symposium in the UK.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 maj 2026 Rapporterad av AI Faktagranskad

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

26 maj 2026 14:54

Genredigerande läkemedel sänker det onda kolesterolet med 62 procent i studie

Relaterade artiklar

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

DNA hairpin molecules lowered cholesterol by 47% in mice by silencing PCSK9, researchers report

Virus injection halts pancreatic tumor growth in trial

UCLA scientists reverse liver damage in mice by removing zombie cells

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Compound X clears Parkinson's proteins in mice brains

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

USC researchers identify compounds targeting Alzheimer’s brain inflammation

Nanoparticles reduced amyloid-β and improved cognition in an Alzheimer’s mouse model, researchers report

Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Trojan horse obesity drug boosts weight loss in mice

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

AI identifies breast cancer drug for multiple viruses

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

ACC and AHA release updated cholesterol management guidelines

Engineered antibody shrinks tumors body-wide in early cancer trial

Denna webbplats använder cookies